Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the U.S. Food and Drug Administration (FDA) had given clearance to…